Posted by Michael Wonder on 24 Jun 2021
Lynparza approved in China for the treatment of BRCA mutated metastatic castration resistant prostate cancer
24 June 2021 - First PARP inhibitor approved in China in advanced prostate cancer.
AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following treatment that included a new hormonal agent (abiraterone, enzalutamide).
